Covered recipient · General Payments record
HEATHER D HARLE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$3,161.37
- Reported across 120 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $790.50 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $283.54 | 20 |
| Alexion Pharmaceuticals, Inc. | $179.90 | 3 |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 1 |
| TG THERAPEUTICS, INC. | $45.20 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $43.03 | 2 |
| SK Life Science, Inc. | $28.54 | 1 |
| ARGENX US, INC. | $24.08 | 1 |
| PFIZER INC. | $21.28 | 1 |
| Biogen, Inc. | $20.48 | 1 |
| Amneal Pharmaceuticals LLC | $19.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $12.32 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880486 | CMS |
| ABBVIE INC. | $4.32 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880488 | CMS |
| ABBVIE INC. | $11.18 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880490 | CMS |
| ABBVIE INC. | $18.76 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880492 | CMS |
| ABBVIE INC. | $0.38 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880494 | CMS |
| ABBVIE INC. | $2.40 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880496 | CMS |
| ABBVIE INC. | $0.44 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880498 | CMS |
| ABBVIE INC. | $0.03 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880500 | CMS |
| ABBVIE INC. | $17.40 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880502 | CMS |
| ABBVIE INC. | $118.06 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880504 | CMS |
| ABBVIE INC. | $7.34 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880506 | CMS |
| ABBVIE INC. | $8.09 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880508 | CMS |
| ABBVIE INC. | $8.27 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880510 | CMS |
| ABBVIE INC. | $23.61 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880512 | CMS |
| ABBVIE INC. | $12.12 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880514 | CMS |
| ABBVIE INC. | $6.42 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880516 | CMS |
| ABBVIE INC. | $6.36 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880518 | CMS |
| ABBVIE INC. | $6.25 | 11/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880520 | CMS |
| ABBVIE INC. | $7.48 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880522 | CMS |
| ABBVIE INC. | $12.31 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103880524 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.09 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093914708 | CMS |
| Alexion Pharmaceuticals, Inc. | $125.00 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093954793 | CMS |
| Alexion Pharmaceuticals, Inc. | $32.81 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094046745 | CMS |
| Amneal Pharmaceuticals LLC | $19.45 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139188290 | CMS |
| ARGENX US, INC. | $24.08 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142122368 | CMS |
| Biogen, Inc. | $20.48 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104816395 | CMS |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150241522 | CMS |
| Novartis Pharmaceuticals Corporation | $20.33 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086852157 | CMS |
| Novartis Pharmaceuticals Corporation | $22.70 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086852171 | CMS |
| PFIZER INC. | $21.28 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131511559 | CMS |
| SK Life Science, Inc. | $28.54 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154135988 | CMS |
| TG Therapeutics, Inc. | $25.66 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136882185 | CMS |
| TG Therapeutics, Inc. | $19.54 | 11/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136882183 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.